Celmatix

New York, United States Founded: 2009 • Age: 17 yrs
Fertility decisions are optimized using data analytics and genomics.

About Celmatix

Celmatix is a Healthcare company based in New York (United States) founded in 2009. Fertility decisions are optimized using data analytics and genomics. Celmatix has raised $24.89 million across 7 funding rounds from investors including Regional Economic Development Councils and Topspin Consumer Partners. The company has 27 employees. Celmatix offers products and services including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Celmatix Inc. Its competitors include Invitae, Myriad Genetics and Genome Medical; 2 of its 3 listed competitors have raised funding.

Company details

Celmatix focuses on womens health. It uses predictive analytics and genomics to create products that help in infertility treatment and proactive fertility management. The company offers POLARIS, a cloud- based analytics platform for optimizing a womans fertility by calculating the personal likelihood of success using various fertility treatment options, tailored to a patients clinical metrics. In addition, the company offers Fertilome, an NGS assay that enables women to evaluate present and future fertility potential. Fertilome analyzes 49 different variants in 32 genes, and is specifically aimed at women who plan to freeze their eggs, have children after the age of 35, or have risk factors that affect fertility such as PCOS, depleted ovarian reserve, endometriosis or other endocrine disorders.

Key Metrics

Products & Services of Celmatix

Celmatix offers a comprehensive portfolio of products and services, including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor.

AMHR2 Agonist Program
Drug Development

Targets ovarian aging and related health issues in women.

Oral FSH Receptor Agonist
Fertility Treatment

Advances infertility therapies through targeted hormone stimulation.

JNK Inhibitor
Pain Management

Addresses inflammation and pain in women's health conditions.

Funding Insights of Celmatix

Celmatix has successfully raised a total of $24.89M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $4.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $24.89M
  • Total Rounds 7
  • Last Round Series C β€” $4.5M
  • First Round $806,129

    (Feb 2011)

  • Investors Count 2

All 7 funding rounds of Celmatix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2017$4.5MSeries C––
Mar 2016$4.8MSeries C––
–
Aug 2015$3.76MSeries C––
–
Dec 2014$5.51MSeries C––
–
Feb 2013$4.01MSeries B––
–
Feb 2012$1.5MSeries A–Topspin Consumer Partners
–
Feb 2011$806,129Series A–Topspin Consumer Partners
–
Valuation history

2 investors in total: 2 institutional.

Investors in Celmatix

Celmatix has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Regional Economic Development Councils and Topspin Consumer Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands.
topspincp.comMamaroneck, USA
regionalcouncils.ny.gov
Premium access

Investor details for Celmatix

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Celmatix

20 people are tracked at Celmatix (4 in leadership, 12 in board & advisors, 4 in team); the tracked headcount is 27.

NameRoleGroup
Charlotte Frank Sage
VP, Clinical Research OperationsLeadership
Elizabeth (Ellie) Amador
Director of Clinical Research OperationsLeadership
Piraye Yurttas Beim
Founder & CEOLeadership
Caterina Clementi
VP, Biological SciencesLeadership
Richard Anderson
Scientific Advisory BoardBoard & advisors
Harald Dinter
Scientific Advisory BoardBoard & advisors
Susan Herbert
Scientific Advisory BoardBoard & advisors
Björn Hock
Scientific Advisory BoardBoard & advisors
Joan-Carles Arce
Scientific Advisory BoardBoard & advisors
Cory Ondrejka
Strategic AdvisorBoard & advisors
David Sable
DirectorBoard & advisors
Linda C. Giudice
Scientific AdvisorBoard & advisors
Roger Gosden
Scientific AdvisorBoard & advisors
Mark Wolters
Strategic AdvisorBoard & advisors
Kevin Lynch
Strategic AdvisorBoard & advisors
Steve Winick
DirectorBoard & advisors
Adrienne Day
CBOTeam
Robert O'Connell
Financial ControllerTeam
Stephen Palmer
CSOTeam
Craig Bolton
General CounselTeam
Premium access

Complete people profiles for Celmatix

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Celmatix

3 dated milestones of Celmatix across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Celmatix is founded.
  2. Funding First funding round of $806K.
  3. Funding Latest funding round, Series C, of $4.5M.

Competitors of Celmatix

Celmatix has 3 listed competitors in our database, 2 of them funded. They include Invitae, Myriad Genetics and Genome Medical.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
invitae.com2010San Francisco, United States$189.56M1,700
Home-based genetic tests for detecting diseases are provided to individuals.
myriad.com1991United States2,700
Molecular diagnostics and personalized medicine for cancer are developed.
genomemedical.com2016Monterey, United States$172.98M84
Genomic testing services are provided clinically and directly to consumers.
Premium access

Detailed competitors of Celmatix

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Celmatix

Websites that share an audience with Celmatix (celmatix.com).

Similar websites

Websites whose visitors overlap most with Celmatix. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cincinnatifertility.com
cincinnatifertility.com
100%
#2,862,129–
reproductivehealthctr.com
reproductivehealthctr.com
100%
–
reproductivefacts.org
reproductivefacts.org
99%
#505,784–
rmia.com
rmia.com
98%
#1,683,967–
okivf.com
okivf.com
98%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Celmatix

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Celmatix (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Celmatix

Premium access

Complete news archive for Celmatix

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Celmatix

Celmatix was founded in 2009 and raised its 1st funding round 2 years after it was founded.

Celmatix is headquartered in New York, United States. It is registered at New York, New York, United States.

Celmatix is a funded company, having raised a total of $24.89M across 7 funding rounds to date. The company's 1st funding round was a Series A of $806.13K, raised on Feb 2011.

Celmatix has 27 employees.

Celmatix focuses on womens health. It uses predictive analytics and genomics to create products that help in infertility treatment and proactive fertility management. The company offers POLARIS, a cloud- based analytics platform for optimizing a womans fertility by calculating the personal likelihood of success using various fertility treatment options, tailored to a patients clinical metrics. In addition, the company offers Fertilome, an NGS assay that enables women to evaluate present and future fertility potential. Fertilome analyzes 49 different variants in 32 genes, and is specifically aimed at women who plan to freeze their eggs, have children after the age of 35, or have risk factors that affect fertility such as PCOS, depleted ovarian reserve, endometriosis or other endocrine disorders.

Celmatix's top competitors include Myriad Genetics, Genome Medical and Invitae.

Celmatix offers AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor.

Celmatix has 2 investors. Key investors include Regional Economic Development Councils, and Topspin Consumer Partners.

Celmatix operates through Celmatix Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available